x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

BioCentury This Week

BioCentury"s streaming commentary on biotech industry trends, plus interviews with KOLs.For three decades, BioCentury has helped biopharma executives and investors make business-critical decisions and build larger networks with peers across the innovation ecosystem.

science life sciences

All Episodes

21:25

Ep. 240 - Chevron Ruling's Impact. Plus: Tumor...

BioCentury This Week ·

2024/07/02

The impact on FDA and the biopharma industry of the Supreme Court’s move to overturn the legal doctrine that courts defer to federal agencies’ interpretations of ambiguous laws will take years to come into focus; for now, the clearest effects of the Chevron ruling will be on disputes over exclusivity and other non-science issues. On the latest BioCentury This Week podcast, BioCentury’s editors analyze the court’s decision, including how FDA could adjust how it operates. The editors also discu...

en-us

24:59

Ep. 239 - Rare Disease Spotlight: MPS & DMD

BioCentury This Week ·

2024/06/25

A biomarker breakthrough could shave years off the development of therapies for a group of devastating, progressive ultrarare diseases. On the latest BioCentury This Week podcast, BioCentury’s editors discuss FDA’s agreement to allow biopharma companies to use a biomarker as the basis for accelerated approval of neuronal mucopolysaccharidoses therapies, which marks an important inflection point, both for MPS and rare diseases in general. The editors also assess FDA’s decision to grant full ap...

en-us

22:01

Ep. 238 - Biosecure Act: The Impact & What's Ahead

BioCentury This Week ·

2024/06/20

After whisking through Washington for the first half of the year, raising alarms, mutating and causing confusion, the Biosecure Act is now on pause. On the latest BioCentury This Week podcast, BioCentury’s editors discuss what the delay for the legislation, which seeks to drive Chinese contract development and manufacturing organizations out of the U.S., means, what will happen next, and how it will impact life sciences companies.View full story: https://www.biocentury.com/article/65277103:09...

en-us

28:43

Ep. 237- Pandemic Prep Problems, Reverse Mergers,...

BioCentury This Week ·

2024/06/18

The avian flu outbreak is a fire drill that is showing how poorly the U.S. is prepared for the next pandemic. On the latest BioCentury This Week podcast, BioCentury's editors recap last week’s BioCentury Show conversation with Rick Bright, including the former BARDA director’s insights on the opportunities for biotechs to help fill voids in surveillance, point-of-care diagnostics, vaccines and therapeutics and the need for the government to provide leadership and funding to empower industry. ...

en-us

26:18

Ep. 236 - BIO Wrap: Biosecure, Japan & Nxera,...

BioCentury This Week ·

2024/06/14

BIO’s annual meeting took place amid heightened industry concerns regarding the Biosecure Act, which took yet another unexpected turn this week. On a special edition of the BioCentury This Week recapping the meeting, BioCentury's editors discuss the latest on the anti-China biopharma legislation, including misperceptions of what the bill seeks to accomplish.Special guest Chris Cargill, the CEO of Nxera Pharma, joins the podcast to discuss the expanded APAC presence at this year’s BIO; Japan’s...

en-us

29:30

Ep. 235 - Psychedelic Setback, FDA's Platform Play &...

BioCentury This Week ·

2024/06/10

A snub by an FDA advisory committee for an MDMA-psychotherapy combination is unlikely to read through to other psychedelic therapies in the pipeline. On the BioCentury This Week podcast, BioCentury’s editors discuss the shortcomings of the Lykos Therapeutics product’s clinical development program and why other psychedelics likely won’t face the same hurdles. The editors also assess FDA’s new platform technology designation and the first-in-human clinical trials described at this year’s Americ...

en-us

28:38

Ep. 234 - Biotech M&A, Biosecure Expands & ASCO Update

BioCentury This Week ·

2024/06/03

Four takeouts with upfront payments north of $1 billion to close out May mark the latest run of VC exits from biotech M&A and help expand the pipelines of large biopharmas in renal, ophthalmic and immunologic indications. On the latest BioCentury This Week podcast, BioCentury’s editors discuss how two of the takeouts -- Asahi Kasei’s buy of Calliditas and Biogen’s acquisition of HI-Bio -- showcase how the renal field is on the rise. Turning to Washington, the editors explain why the House...

en-us

36:00

Ep.233 - ASCO Preview, Rare Diseases & Biogen M&A

BioCentury This Week ·

2024/05/28

A theme among late-breaker presentations at this year’s American Society of Clinical Oncology meeting is the push by companies to move targeted therapies into earlier lines of treatment. On the latest BioCentury This Week podcast, BioCentury’s editors discuss what they’re watching for in ASCO’s headline presentations and deliver highlights from abstracts released late last week as the oncology meeting readies to kick off on Friday.The editors also discuss the interest by FDA’s Janet Woodcock ...

en-us

26:21

Ep.232 - Shake up at BIO. Plus: ASGCT highlights, new...

BioCentury This Week ·

2024/05/20

New BIO CEO John Crowley is reorganizing BIO in a bid to reshape how the organization communicates and enhance its focus on patients. BioCentury’s editors also recap the 24th annual BioEquity Europe conference that was held in San Sebastian, Spain last week, as well as highlights from last week’s American Society of Gene and Cell Therapy (ASGCT) conference. The editors also discuss impressive early data from Endeavor BioMedicines Inc. in idiopathic pulmonary fibrosis (IPF) and Phase Ib obesit...

en-us

32:57

Bonus Content - Derek Lowe Unplugged: AI; Biosecure;...

BioCentury This Week ·

2024/05/16

“I’m a short-term pessimist and a long-term optimist” about the potential for AI to transform drug development, Derek Lowe, author of the In the Pipeline blog, told BioCentury Washington Editor Steve Usdin on the latest BioCentury Show. Lowe's skepticism about claims that AI will rapidly transform the field is driven by a belief that the “problems that we have in the drug industry that we want to solve are almost inversely proportional to the ability of AI to solve them." Lowe also discussed ...

en-us

25:03

Ep. 231 - Biosecure Revised. Plus: Venture Rounds,...

BioCentury This Week ·

2024/05/14

Lawmakers’ changes to the Biosecure Act create breathing room for U.S. biopharma companies to move on from Chinese CDMOs, Washington Editor Steve Usdin said. On the latest BioCentury This Week podcast, Usdin and his BioCentury colleagues discuss what the revisions mean for biotechs and what’s next for the legislation, plus how WuXi AppTec is defending itself against the bill’s allegations. Director of Biopharma Intelligence Paul Bonanos discusses last week’s surge in venture activity, includi...

en-us

31:41

Bonus Content - Ysios' Karen Wagner: How Europe's...

BioCentury This Week ·

2024/05/09

It sounds obvious, but still needs saying, says Ysios Capital's Karen Wagner. “How do you rise above the noise? By having the most spectacular data.” In conversation with Editor in Chief Simone Fishburn on The BioCentury Show, Wagner discussed the theme of the upcoming Bio€quity Europe conference — rising above the noise: in a sea of competition where companies vie for attention among investors and pharmas, what are the characteristics that allow them to differentiate? Wagner explains what sh...

en-us

25:50

Ep. 230 - Bio€quity Europe 2024 Preview

BioCentury This Week ·

2024/05/09

Next week's Bio€quity Europe conference in San Sebastián will focus on how European biotechs can rise above the noise to attract investors, partners and talent. McKinsey & Co.’s Alexandra Zemp and Paula Olazábal of Ysios Capital joined BioCentury to outline the opportunities and challenges faced by Spain’s biopharma ecosystem and preview some of the conference’s networking events, fireside chats and panel discussions. EBD Group's Claire Macht also joined to detail what to expect in terms ...

en-us

28:35

Ep. 229 - ASGCT Preview, Accelerated Approval Plus:...

BioCentury This Week ·

2024/05/07

One of the big themes of this week’s ASGCT meeting will be CAR T cells in cancer and beyond. On the latest BioCentury This Week podcast, BioCentury’s editors preview the American Society of Gene and Cell Therapy’s annual meeting. Much of the CAR T field has reoriented from cancer to autoimmune diseases over the past year. Now, researchers are looking even farther afield. According to abstracts released ahead of ASGCT, the engineered T cell modality may have new benefits to offer patients with...

en-us

23:02

Ep. 228 - Energizing Gene Therapy. Plus: AI Newco,...

BioCentury This Week ·

2024/04/30

en-us

22:42

Ep. 227 - Defending Accelerated Approval. Plus:...

BioCentury This Week ·

2024/04/22

en-us

22:59

Ep. 226 - Vertex’s Alpine Buy, Goldman’s Venture &...

BioCentury This Week ·

2024/04/16

en-us

21:42

Ep. 225 - 2Q Markets Preview & AACR Takeaways

BioCentury This Week ·

2024/04/08

en-us

21:11

Ep. 224 - Biotech IPOs, Avalon & FDA at SCOTUS

BioCentury This Week ·

2024/04/02

en-us

28:14

Ep. 223 - Biosecure, Bruce Booth & Ultrarare Drugs

BioCentury This Week ·

2024/03/26

en-us

349 results

Similar Podcasts

Classic Radio Science Fiction

solgoodmedia.com

Mission to Mars

Inception Point Ai

The 365 Days of Astronomy

365DaysOfAstronomy.org

Creek Devil

william Jevning

UFO Chronicles Podcast

Nik Hunter